Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Step by step instructions to Pick the Right Dental specialist for Your Dental Inserts Technique - 2How on earth did 'Shark Tank' star Kevin O'Leary end up in 'Marty Supreme'? I'll let him explain.
- 3The most effective method to Keep up with Proficient Handshakes in a Computerized World
- 4James Webb Space Telescope spies mysterious high-energy radiation in star nursery
- 5Holden Commodore Turbo BT1 Police Interceptor Offered for Sale in Australia
- Vietnam rethinks its flood strategy as climate change drives storms and devastation
- UN mission says no evidence Hezbollah rearming in southern Lebanon
- Understanding Successful Compromise Standards to Cultivate Agreeable Connections
- Ads promising cosmetic surgery patients a ‘dream body’ with minimal risk get little scrutiny
- Emotional wellness Matters: My Fight with Tension
- Step by step instructions to Get a good deal on Your Rooftop Substitution Venture
- Gauging the Upsides and downsides of Visas: A Complete Aide
- 10 Fundamental Tips and Deceives to Lift Your Cell phone's Exhibition
- Heart disease risk greater for women with a common condition they may not be aware they have
